Abstract | BACKGROUND: METHODS: A total of 216 patients with respiratory or urinary tract infections were enrolled into this multicenter, open-label, randomized controlled clinical study. Each patient was randomly assigned to either the treatment or control group; 106 patients in each group were included in the ITT analyses. The patients were given biapenem 300 mg or imipenem/cilastatin 500 mg/500 mg two or three times daily, i.v. g.t.t. for 7-14 days according to their conditions. RESULTS: The cure and effective rates were 67.92 and 88.68% in the biapenem group and 76.02 and 93.40% in the imipenem/cilastatin group, the bacterial eradication rates were 93.83 and 98.82%, and the adverse-event rates were 6.54 and 7.41%, respectively. There were no significant differences between the two groups (p > 0.05). CONCLUSION:
|
Authors | Bei Jia, Ping Lu, Wenxiang Huang, Chongzhi Li, Ailong Huang, Xiangdong Zhou, Weili Zhang, Guoming Wu, Genfu Zhang |
Journal | Chemotherapy
(Chemotherapy)
Vol. 56
Issue 4
Pg. 285-90
( 2010)
ISSN: 1421-9794 [Electronic] Switzerland |
PMID | 20714145
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2010 S. Karger AG, Basel. |
Chemical References |
- Anti-Infective Agents
- Drug Combinations
- Thienamycins
- Cilastatin
- Imipenem
- Cilastatin, Imipenem Drug Combination
- biapenem
|
Topics |
- Adolescent
- Adult
- Aged
- Anti-Infective Agents
(adverse effects, pharmacology, therapeutic use)
- Bacterial Infections
(drug therapy, microbiology)
- Cilastatin
(adverse effects, pharmacology, therapeutic use)
- Cilastatin, Imipenem Drug Combination
- Drug Combinations
- Female
- Hospitals, Teaching
- Humans
- Imipenem
(adverse effects, pharmacology, therapeutic use)
- Male
- Middle Aged
- Respiratory Tract Infections
(drug therapy, microbiology)
- Thienamycins
(adverse effects, pharmacology, therapeutic use)
- Urinary Tract Infections
(drug therapy, microbiology)
- Young Adult
|